Rates of cardiovascular disease following smoking cessation in patients with HIV infection: Results from the D:A:D study

HIV Medicine

Volumn 12, Issue 7, 2011, Pages 412-421

  Petoumenos, K ^a   Worm, S ^b   Reiss, P ^c   de Wit, S ^d   d'Arminio Monforte, A ^e   Sabin, C ^f   Friis Moller N ^b   Weber, R ^g   Mercie, P ^h   Pradier, C ⁱ   El Sadr, W ^j   Kirk, O ^b   Lundgren, J ^b   Law, Mg ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c STICHTING HIV MONITORING   (Netherlands)

^d SAINT PIERRE UNIVERSITY HOSPITAL   (Belgium)

^e UNIVERSITY OF MILAN   (Italy)

^f ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^g UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^h INSERM   (France)

ⁱ CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

^j Och Spine at New York Presbyterian Hospitals   (United States)

more..

Author keywords

Cardiovascular disease; Cohort study; HIV infection; Myocardial infarction; Smoking cessation

Indexed keywords

ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ANTIRETROVIRUS AGENT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; PROTEINASE INHIBITOR; TRIACYLGLYCEROL;

ANGIOPLASTY; ANTIHYPERTENSIVE THERAPY; ANTIVIRAL THERAPY; ARTICLE; CARDIOVASCULAR DISEASE; CAROTID ENDARTERECTOMY; CHOLESTEROL BLOOD LEVEL; CORONARY ARTERY BYPASS GRAFT; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; FAMILY HISTORY; FEMALE; FOLLOW UP; GENDER; HEART INFARCTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SMOKING; SMOKING CESSATION; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; VIRUS LOAD;

ADULT; ARGENTINA; CARDIOVASCULAR DISEASES; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; EUROPE; FEMALE; HIV INFECTIONS; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RISK FACTORS; SMOKING; SMOKING CESSATION; UNITED STATES;

EID: 79959945809     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2010.00901.x     Document Type: Article

References (31)

1. Grierson J, Thorpe R, Saunders M, Pitts M. HIV Futures4: State of the [Positive] Nation, Monograph Series Number 48. The Australian Research Centre in Sex, Health and Society, Latrobe University, Melbourne, Australia, 2004.
2. Benard A, Bonnet F, Tessier JF et al. Tobacco addiction and HIV infection: toward the implementation of cessation programs. ANRS CO3 Aquitaine Cohort. AIDS Patient Care STDS 2007; 21: 458-468.
3. Duval X, Baron G, Garelik D et al. Living with HIV, antiretroviral treatment experience and tobacco smoking: results from a multisite cross-sectional study. Antivir Ther 2008; 13: 389-397.
4. Tesoriero JM, Gieryic SM, Carrascal A, Lavigne HE. Smoking among HIV positive New Yorkers: prevalence, frequency, and opportunities for cessation. AIDS Behav 2010; 14: 824-835.
5. Mamary EM, Bahrs D, Martinez S. Cigarette smoking and the desire to quit among individuals living with HIV. AIDS Patient Care STDS 2002; 16: 39-42.
6. Crothers K, Goulet JL, Rodriguez-Barradas MC et al. Decreased awareness of current smoking among health care providers of HIV-positive compared to HIV-negative veterans. J Gen Intern Med 2007; 22: 749-754.
7. Friis-Moller N, Weber R, Reiss P et al. Cardiovascular disease risk factors in HIV patients-association with antiretroviral therapy. Results from the DAD study. AIDS 2003; 17: 1179-1193.
8. Crothers K, Griffith TA, McGinnis KA et al. The impact of cigarette smoking on mortality, quality of life, and comorbid illness among HIV-positive veterans. J Gen Intern Med 2005; 20: 1142-1145.
9. Clifford GM, Polesel J, Rickenbach M et al. Cancer risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy. J Natl Cancer Inst 2005; 97: 425-432.
10. Burns DN, Hillman D, Neaton JD et al. Cigarette smoking, bacterial pneumonia, and other clinical outcomes in HIV-1 infection. Terry Beirn Community Programs for Clinical Research on AIDS. J Acquir Immune Defic Syndr Hum Retrovirol 1996; 13: 374-383.
11. Conley LJ, Bush TJ, Buchbinder SP, Penley KA, Judson FN, Holmberg SD. The association between cigarette smoking and selected HIV-related medical conditions. AIDS 1996; 10: 1121-1126.
12. Caiaffa WT, Vlahov D, Graham NM et al. Drug smoking, Pneumocystis carinii pneumonia, and immunosuppression increase risk of bacterial pneumonia in human immunodeficiency virus-seropositive injection drug users. Am J Respir Crit Care Med 1994; 150: 1493-1498.
13. Crothers K, Butt AA, Gibert CL, Rodriguez-Barradas MC, Crystal S, Justice AC. Increased COPD among HIV-positive compared to HIV-negative veterans. Chest 2006; 130: 1326-1333.
14. Kirk GD, Merlo C, O'Driscoll P et al. HIV infection is associated with an increased risk for lung cancer, independent of smoking. Clin Infect Dis 2007; 45: 103-110.
15. Bonnet F, Lewden C, May T et al. Malignancy-related causes of death in human immunodeficiency virus-infected patients in the era of highly active antiretroviral therapy. Cancer 2004; 101: 317-324.
16. Mercie P, Thiebaut R, Lavignolle V et al. Evaluation of cardiovascular risk factors in HIV-1 infected patients using carotid intima-media thickness measurement. Ann Med 2002; 34: 55-63.
17. Friis-Moller N, Sabin CA, Weber R et al. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 2003; 349: 1993-2003.
18. Monforte A, Abrams D, Pradier C et al. HIV-induced immunodeficiency and mortality from AIDS-defining and non-AIDS-defining malignancies. AIDS 2008; 22: 2143-2153.
19. Palella FJ Jr, Baker RK, Moorman AC et al. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr 2006; 43: 27-34.
20. Lewden C, Salmon D, Morlat P et al. Causes of death among human immunodeficiency virus (HIV)-infected adults in the era of potent antiretroviral therapy: emerging role of hepatitis and cancers, persistent role of AIDS. Int J Epidemiol 2005; 34: 121-130.
21. Lloyd-Richardson EE, Stanton CA, Papandonatos GD et al. Motivation and patch treatment for HIV+smokers: a randomized controlled trial. Addiction 2009; 104: 1891-1900.
22. Wolf PA, D'Agostino RB, Kannel WB, Bonita R, Belanger AJ. Cigarette smoking as a risk factor for stroke. The Framingham study. JAMA 1988; 259: 1025-1029.
23. Wannamethee SG, Shaper AG, Whincup PH, Walker M. Smoking cessation and the risk of stroke in middle-aged men. JAMA 1995; 274: 155-160.
24. Tverdal A, Thelle D, Stensvold I, Leren P, Bjartveit K. Mortality in relation to smoking history: 13 years' follow-up of 68, 000 Norwegian men and women 35-49 years. J Clin Epidemiol 1993; 46: 475-487.
25. Rosenberg L, Kaufman DW, Helmrich SP, Shapiro S. The risk of myocardial infarction after quitting smoking in men under 55 years of age. N Engl J Med 1985; 313: 1511-1514.
26. Godtfredsen NS, Holst C, Prescott E, Vestbo J, Osler M. Smoking reduction, smoking cessation, and mortality: a 16-year follow-up of 19, 732 men and women from The Copenhagen Centre for Prospective Population Studies. Am J Epidemiol 2002; 156: 994-1001.
27. Doll R, Peto R, Boreham J, Sutherland I. Mortality in relation to smoking: 50 years' observations on male British doctors. BMJ 2004; 328: 1519.
28. Benard A, Mercie P, Alioum A et al. Bacterial Pneumonia among HIV-infected patients: decreased risk after tobacco smoking cessation. ANRS CO3 Aquitaine Cohort, 2000-2007. PLoS One 2010; 5: e8896.
29. Friis-Moller NRT, Reiss P, Weber R et al. Predicting the risk of cardiovascular disease in HIV-infected patients; The Data-collection on Adverse Effects of Anti-HIV Drugs (D:A:D) Study. Eur J Cardiovasc Prev Rehabil 2010; 17: 491-501.
30. Sabin CA, Worm SW, Weber R et al. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet 2008; 371: 1417-1426.
31. Worm SW, Sabin C, Weber R et al. Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study. J Infect Dis 2010; 201: 318-330.